Cyclin-dependent kinase 5 (Cdk5) is predominantly expressed in neuron and plays an important role in neuronal physiology. Increasing evidence also indicates that Cdk5 may contribute to malignant progression of some types of cancers; however, the underlying mechanism remains elusive. in this study, we found that Cdk5 directly phosphorylated the actin-binding protein adducin-1 (ADD1) at T724 in vitro and in intact cells. The capability of the phosphomimetic T724D mutant to bind to actin filaments was lower than that of wild type ADD1 and the T724A mutant. Cdk5 co-localized with ADD1 at the lamellipodia upon epidermal growth factor (EGF) stimulation.
Results
Cdk5 directly phosphorylates ADD1 at T724. Our in silico analysis suggested that Cdk5 may phosphorylate ADD1 at S431, S600, and T724 ( Supplementary Table S1 ). To validate these putative phosphorylation sites, Cdk5 was overexpressed in HEK293 cells and the phosphorylation of endogenous ADD1 was analyzed by mass spectrometry. Our mass spectrometry analysis revealed that Cdk5 overexpression induced ADD1 phosphorylation at S431, S586, S600 and T724 ( Supplementary Table S2 ). Indeed, Cdk5 directly phosphorylated purified His-tagged ADD1 in vitro (Fig. 1a ). Mutation of ADD1 at T724 caused ~60% decrease in the phosphorylation by Cdk5 (Fig. 1a) , indicating T724 is the major phosphorylation site for Cdk5. To facilitate the detection of T724phosphorylated ADD1, an antibody (anti-ADD1 pT724) specific to ADD1 pT724 was generated (Fig. 1b) . The specificity of this antibody was confirmed by successfully blocking it with a phosphopeptide corresponding to the Thr724 flanking sequences (Fig. 1b ). Co-expression of HA-tagged Cdk5 (HA-Cdk5) and its activator p35 apparently increased ADD1 pT724 in HEK293 cells (Fig. 1c ). Depletion of Cdk5 by short-hairpin RNA (shRNA) in breast cancer cells MDA-MB-231 significantly diminished ADD1 T724 phosphorylation (Fig. 1d ). These results indicate that Cdk5 mainly phosphorylates ADD1 at T724.
Phosphorylation of ADD1 at T724 may decrease its F-actin binding capability. It is known that phosphorylation of ADD1 in the MARCKS-related domain inhibits its F-actin binding ability [25] [26] [27] ; therefore, we examine whether ADD1 T724 phosphorylation affects its F-actin binding capability. His-tagged ADD1 with a deletion of the head domain (His-ADD1-Δhead) was purified and subjected to F-actin co-sedimentation experiment. In the absence of F-actin, purified His-ADD1 and the mutants were soluble and retained in the supernatant (Fig. 2a ). In the presence of F-actin, ADD1 WT and the T724A mutant were co-sediment with F-actin and detected in the pellet, whereas the phosphomimetic mutant (T724D) was retained in the supernatant ( Fig. 2a ). It has been reported that phosphorylation of ADD1 at S726 diminishes its F-actin binding capability 26, 27 . Accordingly, the S726D mutant was not co-sediment with F-actin in our experiments ( Fig. 2a ). To visualize the interaction between ADD1 and F-actin, purified ADD1 was incubated with F-actin and stained for ADD1 and F-actin with anti-ADD1 antibody and phalloidin, respectively. Our confocal microscopy analysis showed that both T724D and S726D mutants bound to F-actin ~55% less than ADD1 WT and the T724A mutant did (Fig. 2b) . These results suggest that the phosphorylation of ADD1 at T724 may diminish its F-actin binding affinity.
Cdk5-mediated phosphorylation of ADD1 at T724 promotes cell migration and invasion.
ADD1 has been shown to localize at the leading edge of lamellipodia of migratory cells 35 . In this study, we showed that upon EGF stimulation, ADD1 co-localized with cortactin (as a marker for lamellipodia) and Cdk5 at the lamellipodia of MDA-MB-231 cells ( Fig. 3 ). EGF induced activation of Cdk5, as manifested by increased Tyr15 phosphorylation, which was accompanied by increased ADD1 T724 phosphorylation in MDA-MB-231 cells ( Fig. 4a ). Depletion of Cdk5 in MDA-MB-231 cells abrogated the effects of EGF on ADD1 T724 phosphorylation ( Fig. 4b ), lamellipodia formation ( Fig. 4c ), and cell migration ( Fig. 4d ). Likewise, depletion of ADD1 apparently inhibited the effects of EGF on lamellipodia formation ( Fig. 5 ), cell migration ( Fig. 6a ), and invasion ( Fig. 6b ). These defects were restored by re-expression FLAG-ADD1 and T724D mutant, but not T724A or S726A mutant (Figs 5 and 6). These results suggest that phosphorylation of ADD1 at both T724 and S726 may be important for EGF-induced cell migration and invasion.
Increased expression of ADD1 and its phosphorylation at T724 and S726 may be correlated with tumor malignancy. Increasing evidence indicates that the expression levels of Cdk5 and its activators are increased in several types of cancers 3 . We found that the expression levels of p35 and ADD1 were higher in metastatic breast cancer cells MDA-MB-231 than in non-metastatic breast cancer cells MCF7 (Fig. 7a ). Likewise, metastatic colorectal cancer cells SW620 showed higher expression of p35 and ADD1 than non-metastatic colorectal cancer cells SW480 did ( Fig. 7b ). We have previously shown that phosphorylation of ADD1 at S726 by PKCδ promotes cell motility 35 . We found in this study that the activation of PKCδ was also elevated in highly metastatic cancer cell lines ( Fig. 7a,b ). The increased expression of ADD1 was correlated with increased phosphorylation at T724 and S726. These results suggest that activation of Cdk5 and PKCδ and phosphorylation of ADD1 at T724 and S726 may be correlated with the metastatic potential of cancer cells.
Discussion
Cdk5 has previously been shown to promote cell migration upon EGF stimulation 39 ; however, the underlying mechanism is not clear. In this study, we identified ADD1 as a novel substrate of Cdk5 ( Fig. 1 ) and demonstrated that ADD1 phosphorylation at T724 by Cdk5 is important for EGF-induced cell migration and invasion in MDA-MB-231 breast cancer cells ( Fig. 6 ). ADD1 is known to bundle and cap F-actin at the barbed ends 18, 20 . Our results suggest that phosphorylation of ADD1 at T724 may diminish its F-actin binding affinity ( Fig. 2) , which may thereby allow F-actin to expose their barbed ends, leading to elongation and remodeling of F-actin. We found that phosphorylation of ADD1 at T724 and S726, both of which are located in the MARCKS-related domain, were increased upon EGF stimulation ( Fig. 5a ). Therefore, it is possible that the phosphorylation of ADD1 at both residues may facilitate dynamic remodeling of the actin cytoskeleton during cell migration upon EGF stimulation. This notion is supported partially by ADD1 co-localization with F-actin at the leading edge of the lamellipodia of migratory cells ( Fig. 3 ).
Cdk5 and its activator p35 expression have been shown to be upregulated in breast cancer cells 4 and correlated with tumor progression and poor prognosis 40, 41 . In addition, depletion of Cdk5 was found to impair actin remodeling in breast cancer cells 4 . In this study, we found that in MDA-MB-231 cells, Cdk5 was activated upon EGF stimulation ( Fig. 4a ) and the depletion of Cdk5 in those cells efficiently abrogated the effects of EGF on lamellipodia formation and cell migration ( Fig. 4b-d ). Our and others results together suggest that Cdk5 may be a critical effector to transmit the EGF signaling, leading to reorganization of the actin cytoskeleton and cell migration in cancer cells. Moreover, we found that the expression of Cdk5 activator p35 and ADD1 were much higher in metastatic breast cancer cells MDA-MB-231 than in non-metastatic breast cancer cells MCF7 (Fig. 7a ), suggesting that aberrant expression of Cdk5 and/or its activator p35 as well as elevated ADD1 phosphorylation at T724 may serve as biomarkers for prognosis of breast cancers. However, this possibility remains to be examined in samples from breast cancer patients.
In this study, we show that Cdk5 phosphorylates ADD1 at T724. The T724 and flanking amino acids are well conserved in ADD2 and ADD3. Because both Cdk5 and ADD2 are enriched in the nervous system, it will be of interest to examine whether Cdk5 phosphorylates ADD2 under physiological or pathological conditions. In fact, it was reported that prior priming phosphorylation of ADD2 by Cdk5 enhances its phosphorylation by glycogen synthase kinase 3, which is important for neurite outgrowth in neurons 42 . Moreover, Cdk5 was shown to phosphorylate the Wiskott-Aldrich syndrome protein-family verprolin homologous protein 1 (WAVE1) and regulate actin polymerization in neurons 43, 44 . The possibility of whether Cdk5 targets WAVE proteins to promote lamellipodia in cancer cells or other non-neuronal cells remains to be tested.
We have previously shown that phosphorylation of ADD1 at S726 by PKCδ promotes cell migration 35 . It is worth noting that the T724A mutant was less phosphorylated at S726 upon EGF stimulation (Fig. 5a ), suggesting that prior priming phosphorylation of ADD1 at T724 by Cdk5 may be important for its phosphorylation at S726 by PKCδ. These results together suggest that Cdk5 and PKCδ may coordinately regulate F-actin organization www.nature.com/scientificreports www.nature.com/scientificreports/ and promote cancer cell migration through ADD1. Indeed, elevated activation of Cdk5 and PKCδ and increased phosphorylation of ADD1 at T724 and S726 were detected in the highly metastatic cancer cells (Fig. 7) . In summary, we demonstrate that Cdk5 directly phosphorylates ADD1 at T724, which is important for cell migration and invasion. This work not only unveils the mechanism of Cdk5 in regulating cell migration and invasion through ADD1, but also highlights the role of ADD1 in cancer progression.
Materials and Methods
Materials. The rabbit polyclonal antibody specific to ADD1 pT724 was generated using synthesized phospho-peptides KLH-CKKKKFRTpPSFLKKS (pT724 peptide) as the antigen (AllBio, Inc., Taichung, Taiwan). The rabbit polyclonal anti-ADD1 pS726 (sc-16736), anti-ADD1 (sc-25731), anti-PKCδ (sc-937), and anti-cortactin (sc-11408) antibodies and mouse monoclonal anti-Cdk5 (sc-249) and anti-β-tubulin (sc-5274) antibodies were purchased from Santa Cruz Biotechnology. The rabbit polyclonal anti-FLAG (F7425) and anti-Cdk5 pY15 (SAB4504276) antibodies and mouse anti-β-actin (A5441) antibody were purchased from Sigma-Aldrich. The rabbit monoclonal anti-p35 (C64B10) antibody and rabbit polyclonal anti-PKCδ pY311 were purchased from Cell www.nature.com/scientificreports www.nature.com/scientificreports/ infection, the corresponding cDNAs were PCR amplified using pCMV-3Tag-3A-ADD1 WT, T724A, T724D, or S726D as the template and then subcloned into the lentiviral vector pLAS3w.Pneo or pLAS3w.Phyg (National RNAi Core Facility, Academia Sinica, Taipei, Taiwan). To construct the plasmid encoding the His-tagged ADD1 ΔHead domain (aa 350-737), cDNAs from pCMV-3Tag-3A-ADD1 ΔHead was subcloned into pET-21d vector (EMD Millipore). The pEGFP-C3-Cdk5 and pcDNA3-p35 were gifts from Dr. Ho Lin (National Chung Hsing University, Taichung, Taiwan). The full-length Cdk5 cDNA was cloned into the BamHI and XbaI sites of the pcDNA3.1(+)-HA(3) vector. cell culture and transient transfection. MDA-MB-231, MCF7, SW480, SW620, and HEK293 cells were obtained from American Type Culture Collection and maintained in DMEM supplemented with 10% fetal bovine serum (Invitrogen). Cell culture and transient transfection were performed as described previously 32 .
Lentiviral production and infection. The lentiviral expression system, consisting of the pLKO-AS1-puromycin (puro) plasmid encoding shRNAs, the pLAS3w.Phyg plasmid, and the pLAS3w. Pneo plasmid, were obtained from the National RNAi Core Facility (Academia Sinica, Taiwan). The target sequence for ADD1 was 5′-GCAGAATTTACAGGACATTAA-3′. The target sequences for Cdk5 were 5′-CCTGAGATTGTAAAGTCATTC-3′ (#1) and 5′-CAGAACCTTCTGAAGTGTAAC-3′ (#2). For MDA-MB-231 cells were infected with lentiviruses expressing shRNAs specific to ADD1 (sh-ADD1) or luciferase (shLuc). FLAG-ADD1 or its mutants were re-expressed in the ADD1-depleted cells (sh-ADD1/ FLAG-ADD1). The cells were suspended in serum-free medium and subjected to the cell migration assay with (+) or without (−) 40 ng/ml EGF in the lower chambers. After 6 h, the migrated cells were fixed, stained, and counted using a light microscope. Representative micrographs are shown. Bars, 100 μm. The number of migrated cells were measured and expressed as percentage relative to the control in the absence of EGF. Values (means ± s.d.) are from three independent experiments. *P < 0.05; **P < 0.01; ***P < 0.001. (b) MDA-MB-231 cells described in (a) were suspended in serum-free medium and subjected to the invasion assay with (+) or without (−) 40 ng/ml EGF in the lower chambers. After 24 h, the cells that migrated through Matrigel were fixed, stained and counted using a light microscope. Representative micrographs are shown. Bars, 100 μm. The number of cells were measured and expressed as percentage relative to the control in the absence of EGF. Values (means ± s.d.) are from three independent experiments. *P < 0.05; **P < 0.01; ***P < 0.001. FLAG-ADD1 WT, T724A, T724D, and S726D expression, FLAG-ADD1 cDNAs were amplified by PCR and then subcloned into the pLAS3w.Pneo vector. For FLAG-ADD1 S726D expression, FLAG-ADD1 S726D cDNA was amplified by PCR and then subcloned into the pLAS3w.Phyg vector. Lentiviral production and infection were performed as described previously 32 . immunoblotting and immunoprecipitation. To prepare whole-cell lysates, cells were lysed with 1% NP-40 lysis buffer (1% NP-40, 20 mM Tris-HCl pH 8.0, 137 mM NaCl, 10% glycerol, and 1 mM Na 3 VO 4 ) containing protease inhibitor cocktail (Roche). Immunoblotting and immunoprecipitation were performed as described previously 33 .
In vitro kinase assay. His-tagged ADD1-Δhead and mutants were expressed in E. coli and purified by chelating Sepharose (Amersham Biosciences, NJ) according to the manufacturer's instructions. Kinase reactions were carried out in 40 μl of kinase buffer (25 mM Tris-HCl, pH7.4, 10 mM MgCl 2 ) containing 10 μCi of γ-32 P-ATP (3000 Ci mmol −1 ; PerkinElmer Life Sciences), 10 ng Cdk5/p35, and purified 0.5 μg His-ADD1 proteins at 25 °C for 20 min. Reactions were terminated by addition of SDS sample buffer, and the 32 P-incorporated proteins were fractionated by SDS-PAGE and visualized by autoradiography. The radioisotope activity was quantified using a phosphoimager system (Pharmacia). f-actin co-sedimentation assay. Purified muscle actin (Cytoskeleton, Inc.) at 0.16 μg/μl in the general actin buffer (5 mM Tris-HCl, pH8.0; 0.2 mM CaCl 2 ) was allowed to polymerize by addition of 1/10 volume (2.5 μl) of the polymerization buffer (500 mM KCl; 20 mM MgCl 2 ; 10 mM ATP) at 25 °C for 60 min. For F-actin co-sedimentation assay, purified His-ADD1-Δhead proteins (final concentration: 0.08 μg/μl) were incubated with F-actin at 25 °C for 30 min and then subjected to centrifugation at 150,000 × g for 20 min at 4 °C. The supernatants were collected and the pellets were dissolved in distilled water. His-ADD1-Δhead proteins in an equal volume of the supernatant and pellet fractions were fractionated by SDS-PAGE, visualized with Coomassie blue stain, and measured using ImageJ software.
Immunofluorescence staining and image analysis. To visualize the binding of ADD1 to F-actin, purified His-ADD1-Δhead proteins (final concentration: 0.04 μg/μl) were incubated with F-actin at 25 °C for 30 min. The mixtures were stained with anti-ADD1 (1:100) and Alexa Fluor 488-Phalloidin (1:100) for 2 h, and followed by Alexa Fluor 546-conjugated secondary antibody for another 2 h. An aliquot (10 μl) was dropped onto a coverslip, semidried at 37 °C, mounted in Anti-Fade Dapi-Fluoromount-G (SouthernBiotech), and visualized with a Zeiss ApoTome2 system. The Fluorescence intensity of ADD1 per 10-μm F-actin was measured using ZEN software.
Figure 7.
Increased expression of ADD1 and its phosphorylation at T724 and S726 may be correlated with tumor malignancy. (a) An equal amount of whole cell lysates from high metastatic MDA-MB-231 and low metastatic MCF7 breast cancer cells was analyzed with immunoblotting with antibodies as indicated. (b) An equal amount of whole cell lysates from high metastatic SW620 and low metastatic SW480 colorectal cancer cells was analyzed with immunoblotting blotting with antibodies as indicated.
